Cybin (CYBN) Competitors $7.52 +0.06 (+0.80%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$7.65 +0.13 (+1.73%) As of 07:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock CYBN vs. REPL, PHAR, SANA, NUVB, AVBP, TRVI, ANAB, IMTX, DAWN, and MRVIShould you be buying Cybin stock or one of its competitors? The main competitors of Cybin include Replimune Group (REPL), Pharming Group (PHAR), Sana Biotechnology (SANA), Nuvation Bio (NUVB), ArriVent BioPharma (AVBP), Trevi Therapeutics (TRVI), AnaptysBio (ANAB), Immatics (IMTX), Day One Biopharmaceuticals (DAWN), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical products" industry. Cybin vs. Its Competitors Replimune Group Pharming Group Sana Biotechnology Nuvation Bio ArriVent BioPharma Trevi Therapeutics AnaptysBio Immatics Day One Biopharmaceuticals Maravai LifeSciences Cybin (NYSE:CYBN) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations. Does the media prefer CYBN or REPL? In the previous week, Replimune Group had 10 more articles in the media than Cybin. MarketBeat recorded 12 mentions for Replimune Group and 2 mentions for Cybin. Replimune Group's average media sentiment score of 0.64 beat Cybin's score of 0.52 indicating that Replimune Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Replimune Group 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in CYBN or REPL? 17.9% of Cybin shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 15.0% of Cybin shares are owned by insiders. Comparatively, 8.8% of Replimune Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend CYBN or REPL? Cybin currently has a consensus target price of $85.00, suggesting a potential upside of 1,030.32%. Replimune Group has a consensus target price of $21.00, suggesting a potential upside of 66.27%. Given Cybin's stronger consensus rating and higher probable upside, equities analysts clearly believe Cybin is more favorable than Replimune Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cybin 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Replimune Group 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Which has higher earnings and valuation, CYBN or REPL? Replimune Group is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCybinN/AN/A-$57.88M-$3.88-1.94Replimune GroupN/AN/A-$247.30M-$3.07-4.11 Which has more risk and volatility, CYBN or REPL? Cybin has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, Replimune Group has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Is CYBN or REPL more profitable? Cybin's return on equity of -37.58% beat Replimune Group's return on equity.Company Net Margins Return on Equity Return on Assets CybinN/A -37.58% -36.59% Replimune Group N/A -57.98%-45.21% SummaryCybin beats Replimune Group on 8 of the 13 factors compared between the two stocks. Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CYBN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYBN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYBN vs. The Competition Export to ExcelMetricCybinPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$173.14M$753.22M$5.51B$20.61BDividend YieldN/A4.84%4.25%3.68%P/E Ratio-1.721.4328.1927.27Price / SalesN/A25.51442.3467.02Price / CashN/A19.5635.5321.88Price / Book0.696.608.234.60Net Income-$57.88M-$4.53M$3.23B$995.22M7 Day Performance-1.05%0.25%-0.57%-1.55%1 Month Performance-2.46%1.56%6.66%4.38%1 Year PerformanceN/A-0.43%27.11%8.12% Cybin Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYBNCybin2.6074 of 5 stars$7.52+0.8%$85.00+1,030.3%N/A$173.14MN/A-1.7250REPLReplimune Group4.139 of 5 stars$9.65+2.7%$20.83+115.9%+14.2%$724.61MN/A-3.14210News CoverageAnalyst ForecastOptions VolumeGap UpHigh Trading VolumePHARPharming Group2.063 of 5 stars$10.47-1.0%$30.00+186.5%+16.6%$719.77M$297.20M-52.35280Gap DownSANASana Biotechnology3.2516 of 5 stars$3.10-2.8%$9.17+195.7%-36.9%$719.27MN/A-3.52380NUVBNuvation Bio3.1357 of 5 stars$2.08-0.5%$7.17+244.6%-34.9%$711.15M$7.87M-0.8960High Trading VolumeAVBPArriVent BioPharma2.2839 of 5 stars$20.17-2.9%$40.00+98.3%+10.5%$710.59MN/A-5.3540Positive NewsTRVITrevi Therapeutics3.8761 of 5 stars$5.95flat$20.88+250.8%+131.4%$697.89MN/A-13.2220ANABAnaptysBio1.6714 of 5 stars$23.45-1.3%$42.38+80.7%-22.1%$697.79M$91.28M-4.84100IMTXImmatics3.0856 of 5 stars$5.53-3.2%$14.67+165.2%-51.2%$694.05M$168.65M-32.53260News CoverageDAWNDay One Biopharmaceuticals2.5606 of 5 stars$6.63-2.5%$29.00+337.4%-58.7%$689.27M$131.16M-9.3460MRVIMaravai LifeSciences3.5144 of 5 stars$2.60-2.6%$6.64+155.3%-72.6%$679.94M$259.18M-2.28610 Related Companies and Tools Related Companies REPL Competitors PHAR Competitors SANA Competitors NUVB Competitors AVBP Competitors TRVI Competitors ANAB Competitors IMTX Competitors DAWN Competitors MRVI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CYBN) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cybin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYBN Stock Alerts